Britta Vormoor

421 total citations
12 papers, 162 citations indexed

About

Britta Vormoor is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Britta Vormoor has authored 12 papers receiving a total of 162 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Public Health, Environmental and Occupational Health and 4 papers in Molecular Biology. Recurrent topics in Britta Vormoor's work include Acute Lymphoblastic Leukemia research (5 papers), CAR-T cell therapy research (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Britta Vormoor is often cited by papers focused on Acute Lymphoblastic Leukemia research (5 papers), CAR-T cell therapy research (4 papers) and Sarcoma Diagnosis and Treatment (3 papers). Britta Vormoor collaborates with scholars based in United Kingdom, Netherlands and Belgium. Britta Vormoor's co-authors include Nicola J. Curtin, Abhishek Sharma, Josef Vormoor, Sarah Wilkinson, Ian Wilson, Helen J. Blair, Chris M. Bacon, Michael A. Batey, Gilberto S. Almeida and Olaf Heidenreich and has published in prestigious journals such as Blood, PLoS ONE and European Journal of Cancer.

In The Last Decade

Britta Vormoor

11 papers receiving 160 citations

Peers

Countries citing papers authored by Britta Vormoor

Since Specialization

Citations

This map shows the geographic impact of Britta Vormoor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Britta Vormoor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Britta Vormoor more than expected).

Fields of papers citing papers by Britta Vormoor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Britta Vormoor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Britta Vormoor. The network helps show where Britta Vormoor may publish in the future.

Co-authorship network of co-authors of Britta Vormoor

This figure shows the co-authorship network connecting the top 25 collaborators of Britta Vormoor. A scholar is included among the top collaborators of Britta Vormoor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Britta Vormoor. Britta Vormoor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial 2026 ·University of Birmingham Research Portal (University of Birmingham) ·Britta Vormoor, Joshua Savage, (unknown), (unknown), (unknown), Geoff Shenton, (unknown), Anna Castleton, (unknown), (unknown), (unknown), Marion Strullu, Ruta Tuckuviene, Pamela Kearns, (unknown), S. Barnett, (unknown), (unknown), (unknown), Tobias Menne, Josef Vormoor	0
2	The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study 2023 ·Blood ·Britta Vormoor, Tobias Menne, Joshua Savage, Amit Patel, Anna Castleton, Adele K. Fielding, Donna Lancaster, (unknown), Nicholas Morley, Geoff Shenton, Gareth J. Veal, Julie Irving, Pamela Kearns, Lucinda Billingham, Josef Vormoor	1
3	Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia 2022 ·Leukemia ·(unknown), Erica Brivio, Harm van Tinteren, Susan R. Rheingold, Allison Barz Leahy, Britta Vormoor, Maureen M. O’Brien, Jeremy D. Rubinstein, Krzysztof Kałwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, Monica López‐Duarte, Bianca F. Goemans, Franco Locatelli, Peter M. Hoogerbrugge, Friso Calkoen, C. Michel Zwaan	13
4	Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial 2022 ·BMJ Open ·Tobias Menne, Daniel Slade, Joshua Savage, Sadie Johnson, Julie Irving, Pamela Kearns, Ruth Plummer, Geoff Shenton, Gareth J. Veal, Britta Vormoor, Josef Vormoor, Lucinda Billingham	9
5	MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance 2021 ·Leukemia ·(unknown), Jessica G. C. A. M. Buijs-Gladdines, Valentina Cordo’, (unknown), Willem K. Smits, Zhongli Chen, (unknown), Guido J.R. Zaman, Maarten Altelaar, Koichi Oshima, Beat Bornhäuser, Jean‐Pierre Bourquin, Jan Cools, Adolfo A. Ferrando, Josef Vormoor, Rob Pieters, Britta Vormoor, Jules P.P. Meijerink	35
6	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia 2021 ·Blood ·(unknown), Erica Brivio, Susan R. Rheingold, Allison Barz Leahy, Britta Vormoor, Maureen M. O’Brien, Jeremy D. Rubinstein, Krzysztof Kałwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, José Luís Fuster, Franco Locatelli, Peter M. Hoogerbrugge, Friso Calkoen, C. Michel Zwaan	2
7	Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement 2020 ·Blood ·Elad Jacoby, Sara Ghorashian, Britta Vormoor, Barbara De Moerloose, Nicole Bodmer, Michael Maschan, (unknown), Bella Bielorai, (unknown), (unknown), Claudia Rössig, Amos Toren, Arend von Stackelberg, Jean‐Pierre Bourquin	1
8	The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL 2020 ·Blood ·(unknown), Jessica G. C. A. M. Buijs-Gladdines, Valentina Cordo’, (unknown), Willem K. Smits, Zhongli Chen, (unknown), Guido J.R. Zaman, Maarten Altelaar, Koichi Oshima, Beat Bornhäuser, Jean‐Pierre Bourquin, Jan Cools, Adolfo A. Ferrando, Josef Vormoor, Rob Pieters, Britta Vormoor, Jules P.P. Meijerink	1
9	Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2 2017 ·Oncotarget ·Britta Vormoor, (unknown), Helen Blair, Abhishek Sharma, Sarah Wilkinson, David R. Newell, Nicola J. Curtin	24
10	Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging 2014 ·PLoS ONE ·Britta Vormoor, (unknown), Michael A. Batey, Gilberto S. Almeida, Ian Wilson, (unknown), Abhishek Sharma, Helen J. Blair, (unknown), Olaf Heidenreich, Josef Vormoor, Ross J. Maxwell, Chris M. Bacon	33
11	Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma 2014 ·Current Opinion in Oncology ·Britta Vormoor, Nicola J. Curtin	39
12	349 Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699) 2012 ·European Journal of Cancer ·Britta Vormoor, Sarah Wilkinson, (unknown), Ruth Plummer, Nicola J. Curtin	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact